· H28 · Myths · 5 min read
Looksmaxxing Peptides, Almost No Patients
The science behind BPC-157 is mostly rats. The melanotan file is mostly hospital case reports.

Looksmaxxing peptides are mostly unapproved drugs with barely any human data behind them. BPC-157, the most hyped, has been given to fewer than 30 people in total, in small uncontrolled pilots. Melanotan shows up in the medical literature mainly as case reports of harm, and the one with a proper trial behind it, retatrutide, is an obesity drug still in development, not what arrives in a vial from a website.
Verdict: Dangerous.
Peptides are the looksmaxxing trend that moved from the gym to the syringe: BPC-157 to “heal”, melanotan to tan, copper peptides for skin, retatrutide to get lean fast. In 2026, pediatricians flagged the slide from mewing to peptides as a concern for teenagers (Mekhail, 2026).
You want a sharper jaw, a darker tan or a faster cut → you order peptides online and inject them → the evidence behind most of them comes from rats, cell dishes and emergency case reports → the changes that show on your face still come from training and losing fat.
BPC-157: 35 animal studies, 1 human one
A 2025 review searched the sports medicine research on BPC-157. Out of 544 articles, 36 met the criteria, and 35 of those were animal experiments. The only human paper was a small look back at knee pain: 7 of 12 patients said an injection was still helping after six months (Vasireddi, 2025).
A pharmaceutics review in 2026 found no approved formulation and no completed mid-stage trial. All the human data added up to fewer than 30 people across three uncontrolled pilot studies (Mateescu, 2026). Those pilots reported no harms, but nothing that small and uncontrolled can show a drug is safe (McGuire, 2025). BPC-157 is not FDA approved and is banned in professional sport.
Melanotan: known mainly for what went wrong
Melanotan is sold on social media as an injectable tan. Dermatologists wrote in 2026 about the unregulated product and its risks (Sidhu, 2026). The human reports are complications: a man whose kidney tissue died from a blocked artery, judged most likely due to melanotan II (Peters, 2020), and another with a prolonged, painful erection whose function hadn’t returned four weeks later (Dreyer, 2019). Nobody has ever run a trial of it for tanning.
Copper peptides: still in the lab
GHK-Cu is already in anti-wrinkle creams. A 2025 review found promising cell studies on collagen and skin repair but a surprising lack of clinical trials, and too little data to say whether it even gets through skin well enough to work (Mortazavi, 2025).
Retatrutide: real results, in a real trial
Retatrutide is the exception with serious data. In a 48-week trial of 338 adults with obesity, people on the drug lost between 8.7% and 24.2% of their body weight depending on dose, against 2.1% on placebo (Jastreboff, 2023). Side effects were mostly mild to moderate stomach problems, and heart rate rose with dose before settling.
That result came from a controlled, company-funded trial with doctors monitoring every patient, at fixed doses of a known, pure drug. A research-chemical vial bought online is a different product. A 2026 review lists what goes wrong in that grey market: contamination, impurities and the wrong dose in the bottle, plus concerns about abnormal blood vessel growth, cancer risk and strain on the heart (Moiz, 2026).
What we’d tell a friend
Skip the peptide shop. If you need to lose a lot of weight, approved medication prescribed by a doctor is a real option. An unlabelled vial with a research-use sticker isn’t. For a leaner face, the proven route is training and eating right (the gym beats every face hack), because your jawline follows your body fat (face yoga made their cheeks fuller).
FAQ
Do peptides improve your looks? No study shows BPC-157, melanotan or copper peptide injections make a face look better. The research on them never measured appearance at all.
Is BPC-157 safe? Nobody knows. Its entire human record is a handful of tiny studies with no comparison groups, it isn’t FDA approved, and sport bans it.
Is melanotan a safe way to tan? No. There is no trial showing it’s safe for tanning, and the published human cases describe serious complications, including kidney damage.
References
- Moiz A, O’Keefe EL, O’Keefe JH. Dangers of injectable peptides and other unregulated “biohacking” drugs. Mo Med. 2026;123(4):337-43. PMID: 42757290.
- Mekhail J, Howard C, Milanaik R. From mewing to peptides: looksmaxxing as an emerging pediatric concern. Pediatrics. 2026;158(3):e2026077705. PMID: 42580741. doi:10.1542/peds.2026-077705
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-95. PMID: 40756949. doi:10.1177/15563316251355551
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. PMID: 42198317. doi:10.3390/pharmaceutics18050625
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-19. PMID: 40789979. doi:10.1007/s12178-025-09990-7
- Sidhu AS, Konig DJ, Yu-Corpuz BX, et al. Unregulated melanotan use promoted via social media: emerging dermatologic and public health risks. Int J Dermatol. 2026;65(6):1343-4. PMID: 41559011. doi:10.1111/ijd.70286
- Peters B, Hadimeri H, Wahlberg R, et al. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-61. PMID: 31953620. doi:10.1007/s13730-020-00447-z
- Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. PMID: 30796078. doi:10.1136/bcr-2018-227644
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts. 2025;15:30071. PMID: 39963574. doi:10.34172/bi.30071
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514-26. PMID: 37366315. doi:10.1056/NEJMoa2301972
Cover: screenshot of a TikTok video, shared as commentary.



